Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.
Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...
The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.
BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...
Kelun-Biotech’s Sac-TMT has met its primary endpoint of PFS improvements in combination with MSD’s Keytruda in comparison to the checkpoint inhibitor alone in a Phase III trial. Image credit: Butusova ...
Takeda Pharmaceuticals’ dengue vaccine, Qdenga, has demonstrated long-term efficacy in preventing infections and hospitalisations in a seven-year Phase III study. Image credit: SILVIA MAQQ via ...
Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback